SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.37
-0.03 (-0.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close11.40
Open11.46
Bid10.75 x 800
Ask12.91 x 1400
Day's Range11.09 - 11.78
52 Week Range5.52 - 18.23
Volume23,129
Avg. Volume79,825
Market Cap199.246M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire16 days ago

    Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review

    CAMBRIDGE, Mass., May 09, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire24 days ago

    Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Spero (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Spero, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $11.18 per share, which is equal to the closing price of Spero’s common stock on April 30, 2019.  Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to each employee’s continued employment with Spero on such vesting dates.  The options are subject to the terms and conditions of Spero’s 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

  • GlobeNewswire2 months ago

    Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases

    CAMBRIDGE, Mass., April 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire2 months ago

    Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

    CAMBRIDGE, Mass., March 29, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire2 months ago

    Spero Announces Appointment of Cynthia Smith to its Board of Directors

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced the appointment of Cynthia Smith to its Board of Directors, effective as of today. “We are pleased to welcome Cynthia to our Board of Directors,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

  • Business Wire2 months ago

    Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review

    Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19

  • GlobeNewswire3 months ago

    Spero Therapeutics to Present at March Investor Conferences

    Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.  Spero has begun start-up activities for the ADAPT-PO Phase 3 clinical trial of SPR994 for the treatment of complicated urinary tract infections and anticipates opening trial sites to support study enrollment in the first quarter of 2019. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of non-tuberculous mycobacterial (NTM) infections.  In January 2019, Spero initiated a Phase 1 clinical trial of SPR720 in healthy subjects and expects top-line data from this trial in the second half of 2019.

  • GlobeNewswire3 months ago

    Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

    CAMBRIDGE, Mass., Feb. 26, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire4 months ago

    Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

    “With the FDA’s acceptance of our IND application for SPR994, we are excited to continue our Phase 3 initiation efforts, including opening clinical trial sites for enrollment in the U.S.," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.

  • GlobeNewswire4 months ago

    Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial

    “SPR720 is a promising drug candidate that has the potential to become the first approved oral treatment for NTM infections. NTM infections cause chronic, debilitating disease and represent an area of high unmet need as there are no specifically approved orally administered treatment options,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics. The Phase 1 clinical trial evaluating SPR720 is a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts.

  • GlobeNewswire5 months ago

    Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

    SPR206 and SPR741, two intravenous (IV)-administered product candidates from Spero’s Potentiator Platform, are being developed as innovative options to treat MDR Gram-negative bacterial infections.  Based on microbiological and in vivo testing, Spero believes that SPR206 has the potential to offer a broad-spectrum of activity, including against extensively drug-resistant (XDR) bacterial strains, together with improved safety and tolerability compared with other molecules in its class. Spero initiated a Phase 1 clinical trial of SPR206 in December 2018, designed as a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects, and expects top-line data from this trial in the second half of 2019.  Data from investigational new drug (IND)-enabling studies, together with data presented at the ESCMID/ASM Conference in September 2018, collectively demonstrate SPR206’s favorable safety profile and in vitro activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa.

  • GlobeNewswire5 months ago

    Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced the results of its Type B / pre-IND / pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) regarding SPR994 for the oral treatment of complicated urinary tract infections (cUTI). Based on its discussions with the FDA, Spero believes that positive results from a single pivotal Phase 3 clinical trial of SPR994 in cUTI demonstrating a 10% non-inferiority margin would support the approval of SPR994 for the treatment of cUTI.

  • GlobeNewswire6 months ago

    New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire7 months ago

    Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview

    Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08,.

  • GlobeNewswire7 months ago

    Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial

    Spero Therapeutics, Inc. (SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. SPR720 was assessed in a series of non-clinical studies, including IND-enabling 28- and 31-day GLP toxicology studies in non-human primates and rats, respectively, and safety pharmacology studies.